We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
Read MoreHide Full Article
Stereotaxis, Inc. (STXS - Free Report) and Shanghai MicroPort EP Medtech Co., Ltd. announced the receipt of regulatory approval from China’s National Medical Products Administration (“NMPA”) for the Magbot Magnetic Navigation Ablation Catheter last Monday. Stereotaxis had previously announced its collaboration with MicroPort EP in August 2021.
It is worthwhile to note that the Magbot Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed and developed by MicroPort EP in collaboration with Stereotaxis. The catheter works exclusively and in conjunction with Stereotaxis’ robotic systems, including the recently NMPA-approved Genesis RMN and MicroPort EP’s Columbus 3D EP Mapping System.
MicroPort EP will initiate commercial launch of Magbot in China through its existing sales team focused on the electrophysiology community, while Stereotaxis will also benefit from the proceeds from Magbot adoption.
The latest regulatory clearance is a significant stepping stone for Stereotaxis to strengthen its foothold in the global cardiovascular care space.
Likely Trend of STXS Stock Following the News
Following the announcement on Dec. 9, shares of the company gained nearly 5.9% till Friday’s trading.
Historically, the company has gained a topline boost from its various regulatory clearances. We expect market sentiment on the stock to continue to remain positive around this announcement, too.
Stereotaxis currently has a market capitalization of $198.3 million. Its current cash flow growth of 13.4% is favorable against the industry’s negative growth. In the last reported quarter, STXS delivered a negative earnings surprise of 60%.
Significance of Stereotaxis’ NMPA Approval
According to Stereotaxis’ management, Magbot incorporates advanced design features that are expected to enhance the efficiency, effectiveness and safety of robotic magnetic catheter ablation. Robotically navigated using low-intensity magnetic fields, the Magbot catheter will likely be able to reach areas of the heart that are otherwise difficult to access with traditional methods and to maintain precise positioning and stability on cardiac anatomy with high accuracy.
Per MicroPort EP’s management, the approval of the Magbot Catheter signifies a major breakthrough for MicroPort EP in cardiac electrophysiology and a significant milestone for robotic navigation technology in China. Its recent technological advances with Stereotaxis are expected to offer a safer and more precise minimally-invasive treatment solution for complex arrhythmia patients.
Industry Prospects in Favor of STXS
Per a report by Grand View Research, the global cardiovascular devices market is valued at $53.67 billion in 2024 and is projected to witness a CAGR of 8.4% between 2025 and 2030. Factors like increasing cardiovascular disorders, an increase in the availability of affordable and effective devices, and rising demand for minimally-invasive procedures are likely to drive the market.
Given the market potential, the latest regulatory clearance is expected to provide a significant boost to Stereotaxis’ business.
Stereotaxis’ Notable Developments
Last month, Stereotaxis, along with MicroPort EP, received China’s NMPA approval for the Genesis Robotic Magnetic Navigation (RMN) System.
The same month, Stereotaxis announced that physicians at the Hospital da Luz in Lisbon, Portugal, had successfully treated the first patients using the advanced Genesis RMN System.
STXS’s Share Price Performance
Shares of the company have gained 45.4% in the past year compared with the industry’s 7.7% rise and the S&P 500's 28.6% growth.
Image Source: Zacks Investment Research
Stereotaxis’ Zacks Rank & Key Picks
Currently, STXS carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Cardinal Health, Inc. (CAH - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) .
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 11.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cardinal Health’s shares have gained 16.1% compared with the industry’s 4.9% rise in the past year.
Merit Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12%. MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average being 6.4%.
Merit Medical has gained 44.6% compared with the industry’s 4.9% rise in the past year.
LeMaitre Vascular, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21%. LMAT’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.1%.
LeMaitre Vascular’s shares have rallied 68.2% compared with the industry’s 13.9% rise in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
Stereotaxis, Inc. (STXS - Free Report) and Shanghai MicroPort EP Medtech Co., Ltd. announced the receipt of regulatory approval from China’s National Medical Products Administration (“NMPA”) for the Magbot Magnetic Navigation Ablation Catheter last Monday. Stereotaxis had previously announced its collaboration with MicroPort EP in August 2021.
It is worthwhile to note that the Magbot Catheter is a single-use magnetic saline-irrigated radiofrequency ablation catheter designed and developed by MicroPort EP in collaboration with Stereotaxis. The catheter works exclusively and in conjunction with Stereotaxis’ robotic systems, including the recently NMPA-approved Genesis RMN and MicroPort EP’s Columbus 3D EP Mapping System.
MicroPort EP will initiate commercial launch of Magbot in China through its existing sales team focused on the electrophysiology community, while Stereotaxis will also benefit from the proceeds from Magbot adoption.
The latest regulatory clearance is a significant stepping stone for Stereotaxis to strengthen its foothold in the global cardiovascular care space.
Likely Trend of STXS Stock Following the News
Following the announcement on Dec. 9, shares of the company gained nearly 5.9% till Friday’s trading.
Historically, the company has gained a topline boost from its various regulatory clearances. We expect market sentiment on the stock to continue to remain positive around this announcement, too.
Stereotaxis currently has a market capitalization of $198.3 million. Its current cash flow growth of 13.4% is favorable against the industry’s negative growth. In the last reported quarter, STXS delivered a negative earnings surprise of 60%.
Significance of Stereotaxis’ NMPA Approval
According to Stereotaxis’ management, Magbot incorporates advanced design features that are expected to enhance the efficiency, effectiveness and safety of robotic magnetic catheter ablation. Robotically navigated using low-intensity magnetic fields, the Magbot catheter will likely be able to reach areas of the heart that are otherwise difficult to access with traditional methods and to maintain precise positioning and stability on cardiac anatomy with high accuracy.
Per MicroPort EP’s management, the approval of the Magbot Catheter signifies a major breakthrough for MicroPort EP in cardiac electrophysiology and a significant milestone for robotic navigation technology in China. Its recent technological advances with Stereotaxis are expected to offer a safer and more precise minimally-invasive treatment solution for complex arrhythmia patients.
Industry Prospects in Favor of STXS
Per a report by Grand View Research, the global cardiovascular devices market is valued at $53.67 billion in 2024 and is projected to witness a CAGR of 8.4% between 2025 and 2030. Factors like increasing cardiovascular disorders, an increase in the availability of affordable and effective devices, and rising demand for minimally-invasive procedures are likely to drive the market.
Given the market potential, the latest regulatory clearance is expected to provide a significant boost to Stereotaxis’ business.
Stereotaxis’ Notable Developments
Last month, Stereotaxis, along with MicroPort EP, received China’s NMPA approval for the Genesis Robotic Magnetic Navigation (RMN) System.
The same month, Stereotaxis announced that physicians at the Hospital da Luz in Lisbon, Portugal, had successfully treated the first patients using the advanced Genesis RMN System.
STXS’s Share Price Performance
Shares of the company have gained 45.4% in the past year compared with the industry’s 7.7% rise and the S&P 500's 28.6% growth.
Image Source: Zacks Investment Research
Stereotaxis’ Zacks Rank & Key Picks
Currently, STXS carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Cardinal Health, Inc. (CAH - Free Report) , Merit Medical Systems, Inc. (MMSI - Free Report) and LeMaitre Vascular, Inc. (LMAT - Free Report) .
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 10.2%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 11.2%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Cardinal Health’s shares have gained 16.1% compared with the industry’s 4.9% rise in the past year.
Merit Medical, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12%. MMSI’s earnings surpassed estimates in each of the trailing four quarters, with the average being 6.4%.
Merit Medical has gained 44.6% compared with the industry’s 4.9% rise in the past year.
LeMaitre Vascular, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21%. LMAT’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.1%.
LeMaitre Vascular’s shares have rallied 68.2% compared with the industry’s 13.9% rise in the past year.